PharmaCyte Biotech (QB) Stock Price

0.0009 (6.62%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
PharmaCyte Biotech Inc (QB) PMCB OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0009 6.62% 0.0145 16:44:56
Open Price Low Price High Price Close Price Prev Close
0.0135 0.0135 0.0149 0.0145 0.0136
Bid Price Ask Price Spread News
0.0137 0.0167 0.003 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
222 11,265,195 $ 0.014161 $ 159,530 - 0.004 - 0.142
Last Trade Time Type Quantity Stock Price Currency
15:59:34 108,550 $ 0.0145 USD

PharmaCyte Biotech (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 33.85M 2.33B - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
93.24k $ - 0.00% - -

more financials information »

PharmaCyte Biotech (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PMCB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.02050.02690.0120.017272546,980,299-0.006-29.27%
1 Month0.00450.02690.00450.014387827,473,7690.01222.22%
3 Months0.00990.02690.0040.010372216,969,2130.004646.46%
6 Months0.0210.1420.0040.012281319,266,536-0.0065-30.95%
1 Year0.05020.1420.0040.016167412,500,126-0.0357-71.12%
3 Years0.067350.1420.0040.02458955,553,750-0.05285-78.47%
5 Years0.073750.16890.0040.03677224,474,008-0.05925-80.34%

PharmaCyte Biotech (QB) Description

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is also exploring the use of beta islet cells to treat Type 1 and insulin-dependent Type 2 diabetes. The encapsulation of these cells will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.